长效干扰素序贯恩替卡韦与单用恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的比较

A Comparison of Sequential Treatment by Peg-Interferon and Entecavir with Entecavir Mono-Therapy to Chronic Hepatitis B with Positive HBeAg

目的观察和比较长效干扰素序贯恩替卡韦与单用恩替卡韦治疗HBe Ag阳性慢性乙型肝炎疗效。方法收集60例HBe Ag阳性慢性乙型肝炎患者并分为2组(各30例),其中序贯治疗组予以长效干扰素治疗24周,再序贯恩替卡韦治疗24周,恩替卡韦组单用恩替卡韦治疗48周,比较48周时2组患者疗效的差别。结果 2组患者的HBV DNA阴转率差异无统计学意义(χ2=1.92,P=0.166);ALT复常率差异无统计学意义(χ2=0.7407,P=0.389);序贯治疗组患者的HBe Ag转换率高于恩替卡韦组(χ2=5.079 4,P=<0.05)。结论与单用恩替卡韦相比,序贯治疗在免疫控制方面能取得更为理想的疗效。

OBJECTIVE To compare the curative effect of sequential treatment by peg-interferon and entecavir with entecavir mono-therapy to chronic hepatitis B with positive HBe Ag. METHODS A total of 60 patients of chronic hepatitis B with positive HBe Ag were collected,and then were equally divided into 2 groups. Patients in one group were treated by peg-interferon for 24 weeks,and followed up by entecavir for 24 weeks,while patients in another group were treated by entecavir for 48 weeks. Then the curative effect of 2 groups was compared. RESULTS There was no significant difference in HBV DNA seroconversion rates（ χ2= 1. 92,P = 0.166） and ALT recovery rate（ χ2= 0. 7407,P = 0. 389） between 2 groups. The HBe Ag seroconversion rate of sequential group was higher than that of the entecavir group（ χ2= 5. 0794,P〈 0. 05）. CONCLUSION Compared with the treatment of entecavir monotherapy,sequential treatment can get better curative effect in immunity control.